Hymovis Special Precautions

General: Strict aseptic injection technique should be employed during the administration of HYMOVIS.
The safety and effectiveness of the HYMOVIS in joints other than the knee have not been tested.
The effectiveness of repeat treatment cycles of HYMOVIS has not been established.
The safety and effectiveness of the use of HYMOVIS concomitantly with other intra-articular (IA) injections have not been established.
STERILE CONTENTS. The pre-filled syringes are intended for single use only. The contents of the syringe are sterile and should be used immediately after opening. Discard any unused HYMOVIS. Do not re-sterilize.
Do not use HYMOVIS if the package has been opened or damaged.
HYMOVIS should be stored in its original package at room temperature (below 77°F/25°C). DO NOT FREEZE.
It is recommended to remove joint effusion, if present, before injecting HYMOVIS.
Only properly licensed medical professionals trained in accepted injection techniques for delivering agents into the knee joint should inject HYMOVIS for the indicated use.
Transient pain or swelling may occur after the intra-articular injection.
It is recommended that patients avoid strenuous or prolonged (i.e., more than one hour) physical activities within 48 hours following the intra- articular injection.
Use in Pregnancy: The safety and effectiveness of the use of HYMOVIS in pregnant women has not been tested.
Use in Lactation: It is not known if HYMOVIS is excreted in human milk. The safety and effectiveness of the use of the product in lactating women has not been tested.
Use in Children: The safety and effectiveness of the use of HYMOVIS have not been tested in children (21 years of age or younger).